Kodiak Sciences (KOD)

• Market cap: $455M
• 1 day: -0.35%
• 5 days: 1.76%
• 1 month: 49.40%
• 3 months: 227.65%
• 6 months: 243.25%
• Year to date: 172.01%
• 1 year: 210.04%
• 5 years: -87.10%
• 10 years: -14.86%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.

Employees: 108

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

8% more capital invested

Capital invested by funds: $95.1M [Q2] → $103M (+$7.74M) [Q3]

2.19% less ownership

Funds ownership: 77.04% [Q2] → 74.85% (-2.19%) [Q3]

8% less funds holding

Funds holding: 105 [Q2] → 97 (-8) [Q3]

10% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 29

28% less call options, than puts

Call options by funds: $31K | Put options by funds: $43K

40% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 20

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 65% downside
• Avg. target: $9 4% upside
• High target: $20 131% upside

3 analyst ratings

• positive: 1 33%
• neutral: 1 33%
• negative: 1 33%

Jefferies Michael Yee 10% 1-year accuracy 1 / 10 met price target	131% upside $20	Buy Upgraded	9 Dec 2024
Barclays Gena Wang 13% 1-year accuracy 4 / 30 met price target	54% downside $4	Underweight Maintained	15 Nov 2024
HC Wainwright & Co. Matthew Caufield 24% 1-year accuracy 12 / 50 met price target	65% downside $3	Neutral Reiterated	15 Nov 2024